Home
    Webcasting
    Registration
    Accommodation
    Contact
     Home
     Scientific Committee
     Welcome Note
     Topics
     Faculty
     Satellite Symposia
         Webcasting
     Timetable & Program
         Friday, February 6, 2009
         Saturday, February 7, 2009
         Sunday, February 8, 2009
     Poster Presentation Schedule
         Group A
         Group B
         Poster Presentation Guidelines
         E-Posters
     Congress Prize
         Awardees
     CME
     Registration
     Invitation Letter
     Accommodation
     Accompanying Persons Program
     Sponsorship & Exhibition
     Sponsors
     General Information
         Before you travel ...
     Official Airline Network
     Italian Agent
     Contact Us
The 2nd World Congress on
Controversies in Urology (CURy)
Lisbon, Portugal, February 5- 8, 2009
 
  Saturday, February 7, 2009 Print

Saturday, February 7, 2009
             
08:30-10:00 Session 10
Hall A
BLADDER CANCER:
NON-MUSCLE INVASIVE BLADDER TUMORS
Chairperson:
M. Marberger, Austria    
                          
Capsule:
How can we improve diagnosis and treatment of non-muscle invasive bladder tumors?
 
08:30-08:45
 
 
08:45-09:00
 
 
09:00-09:15
 
 
09:15-09:30
 
 
09:30-09:45
Improving diagnosis
M. Burger, Germany
 
Grading, Staging, Prognosticators: To be understood by clinicians
E. Comperat, France
 
pTaG1: Follow-up and management of recurrent tumors
Y. Fradet, Canada
 
Update on topical therapy
F. Witjes, The Netherlands
 
High grade non-muscle invasive TCC: When is more evaluation / treatment needed?
M. Brausi, Italy
 
        
09:45-10:00 Discussion
M. Marberger, Austria
 
  
        
 
08:30-10:00 Session 11
Hall B

PROSTATE CANCER: LOCALLY ADVANCED

Chairpersons:
F. Debruyne, The Netherlands
S. Egawa, Japan
                    
Capsule:
Does surgery have a role in the treatment of locally advanced prostate cancer?
 
 
08:30-08:40
08:40-08:50

MRI of the prostate: Does it dictate treatment?

Yes: P. Mulders, The Netherlands
No: A. Alcaraz, Spain
 
                
08:50-09:10
 
 
 
 
 
09:10-09:30
Debate: Locally advanced disease
 
Is there a role for surgery?
Yes: H. Huland, Germany
No: A. Sella, Israel
 
Extension of Lymph-node dissection
L. Boccon-Gibod, France
U. Studer, Switzerland
 
             
09:30-09:45
 
 
09:45-10:00
Can we predict the outcome of treatment of locally advanced prostate cancer?
Z. Dotan, Israel
    
Surgery combined with hormones/radiation
L. Turkeri, Turkey
      
          
            
            
10:00-10:30
Coffee Break and Poster Viewing
        
     
     
10:30-11:30 Session 12
Hall A

PROSTATE CANCER: HRPC

Chairpersons:
N. Fleshner, Candada
I. Sinescu, Romania 
                 
Capsule:
Have we improved outcomes for patients with HRPC in recent years? 
 
10:30-10;45

Are Antagonists beneficial for HRPC patients?

P. Iversen, Denmark

F. Debruyne, The Netherlands
 
           
10:45-11:10
Debate: Chemotherapy for HRPC
 
When should it be initiated?
For how long?
Is there an age limit?
Its role in an asymptomatic patient
Should hormonal treatment be continued?
 
Moderator: N. Fleshner, Canada
 
Panelists:
J. Fitzpatrick, Ireland
C. Sternberg, Italy
P. Iversen, Denmark
N. Mottet, France
 
                   
 11:10-11:20
 
 
11:20-11:30
Debate: The Management of Chemotherapy failures
2nd Line Chemotherapy
J. Bellmunt, Spain
Novel treatment approaches
A. Sella, Israel
 
          

          
  
10:30-11:30 Session 13
Hall B UPPER TRACT UROTHELIAL CANCER
Chairpersons:
P. Rischmann, France
M. Sosnowski, Poland
       
Capsule:
Are we underutilizing minimally invasive approaches for Upper Tract TCC?
Is there a place for conservative surgical treatment?
   
 
 
10:30-10:40
10:40-10:50
 
 
10:50-11:10
 
Debate: Endoscopic treatment: Antegrade vs. retrograde
 
Antegrade: P. Geavlete, Romania
Retrograde: D. Tolley, UK
 
BCG/MMC irrigation of the upper tracts:
Pro: J. Palou, Spain
Con: A. Zlotta. Canada
 
                
 
 
11:10-11:20
11:20-11:30
Debate: Segmental ureterectomy vs. Nephroureterectomy
 
Segmental ureterectomy: J. Irani, France
Nephroureterectomy: P. Geavlete, Romania
 
    
       
 
11:30-13:00 Session 14
Hall A
TREATMENT STRATEGIES IN ADVANCED PROSTATE CANCER / GU MALIGNANCIES:
THE USE OF BISPHOSPHONATE ACROSS THE CONTINUUM
Chairperson:
J. Fitzpatrick, Ireland
                           
Capsule:
Are there new strategies in the approach of bone metastasis in prostate cancer?
 
Welcome & Introduction
            
Case-based presentation:
 
Are the extended benefits of Bisphosphonates Treatment worth the long-term treatment?
M. Colombel, France
C. Sternberg, Italy
F. Saad, Canada
A. Tubaro, Italy
 
              
 
Is the prevention of Bone Metastasis possible in Prostate Cancer and GU Malignancies?
Pro: F. Saad, Canada
Con: A. Tubaro, Italy
 
           
     Q&A & Closing
          
      
 
11:30-13:00 Session 15
Hall B PRACTICAL TIPS IN MALE AND FEMALE INCONTINENCE
Chairpersons:
F. Cruz, Portugal
D. Pushkar, Russia
                               
Capsule:
Current approaches to surgical treatment of urinary incontinence: What else have we learned?
 
 
11:30-11:50
 
 
 11:50-12:10
 
 
Female Incontinence
Pitfalls of TVT
M. Dambros, Brazil
 
Vaginal approach for Pelvic Organ Prolapse (POP): Tips and tricks
D. Pushkar, Russia
 
            
 
12:10-12:30
Injectables for male and female Incontinence
What, when, where and how many?
D. Pushkar, Russia
 
          
 
12:30-12:45
 
 
 12:45-13:00 
Male Incontinence
Failures with Artificial Urinary Sphincter
J. Heesakkers, The Netherlands
 
Male slings: Are they still there?
F. Cruz, Portugal
 
                     
          
13:00-13:10 Best Abstract Award Ceremony
          
13:10-14:00
Lunch Break and Poster Viewing
 
    
 
14:00-15:30 Session 16
Hall A

BLADDER CANCER: INVASIVE DISEASE

Chairpersons:
R. Hautmann, Germany
C. Llorente, Spain
                            
Capsule:
Can we improve the results of radical cystectomy and bladder substitution?
 
 
 
 
14:00-14:15
14:15-14:30

Debate: Pathological assessment and clinical significance of prostatic involvement by TCC

 
Pathologist's view: E. Comperat, France
Urologist's view: C. Llorente, Spain
 
          
 
 
 
14:30-14:40
14:40-14:50
14:50-15:00
Debate: Bladder substitution
 
How to obtain good results with orthotopic bladder substitution
H. Botto, France
R. Hautmann, Germany
U. Studer, Switzerland
 
       
 
 
 
 
15:00-15:10
15:10-15:20
15:20-15:30
Debate: Cystectomy
 
Open to laparoscopic and robotic surgery: Why consider a change?
 
Open surgery: A. Stenzl, Germany
Laparoscopic surgery: F. Porpiglia, Italy
Robotic surgery: T. Piechaud, France
 
        
     
      
14:00-15:30 Session 17
Hall B

TRICKS OF THE TRADE:

SURGERY FOR KIDNEY CANCER

Chairpersons:
M. Marberger, Austria
A. Akdas, Turkey
        
Capsule: What is left for open nephrectomy?
     
 
 
14:00-14:10
 
14:10-14:20
Debate: Open vs. laparoscopic radical nephrectomy
 
Open nephrectomy
O. Nativ, Israel
Laparoscopic nephrectomy
G. Guazzoni, Italy
 
          
14:20-14:50
Debate: Laparoscopic nephrectomy in difficult situations: Is there a limit?
 
Obesity
Hilar and intrarenal tumors
Small lesion in the single kidney
Tumors over 7 cm in size
Locally advanced disease
Previous operations
 
Moderator: M. Marberger, Austria
 
Panel: 
A. Finelli, Canada
G. Guazzoni, Italy
A. Nadu, Israel
 
             
 
 
14:50-15:00
 
 
 
 
15:00-15:10
15:10-15:20
15:20-15:30
 
Debate: Partial nephrectomy
 
The significance of ischemia and positive margins
M. Marberger, Austria
 
Open vs. Laparoscopic vs. Robotic partial nephrectomy
 
Open: O. Nativ, Israel
Laparoscopic: A. Finelli, Canada
Robotic: A. Mottrie, Belgium
         
                 
15:30-16:30 Session 18
Hall A

MEET THE EXPERTS:

CASE DISCUSSION ON ADVANCED PROSTATE CANCER

Chairperson:
J. Ramon, Israel
J. Bellmunt, Spain   
                          
Capsule:
Why so many options and limited consensus?  Are the guidelines not useful or inappropriate?
 
PSA above 20 ng/ml at diagnosis
Locally advanced disease by MRI only
Clinically localized disease with PSA above 100 ng/ml
Failure of PSA to fall to undetectable following surgery
Pathological T3a with positive margins and undetectable PSA
Post radiotherapy and positive DRE
Gleason's 7 (3+4) pathology T3a, N1, negative margins and undetectable PSA
 
Panel

M. Brausi, Italy

S. Egawa, Japan

J. Fitzpatrick, Ireland

K. Miller, Germany

F. Rischmann, France
E. Solsona, Spain
 
         
       
     
15:30-16:30 Session 19
Hall B

ENDO-UROLOGY AND NEPHROLITHIASIS

Chairpersons:
D. Tolley, UK
P. Dinis, Portugal
                         
Capsule:
Can we choose from so many opinions on how to treat ureteric stones and UPJ obstruction?
 
 
 
 
 
 
 
15:30-15:45
15:45-16:00
 
Debate: Ureteric stone
 
When to treat, how to treat?
Is there a place for medical treatment?  When?  Which treatment?
 
Moderator: D. Tolley, UK
 
M. Marberger, Germany
O. Traxer, France
 
                       
 
 
16:00-16:10
 
 
16:10-16:20
 
 
16:20-16:30
Debate: UPJ obstruction
 
Is endopyelotomy still indicated?
P. Geavlete, Romania
Laparoscopic pyeloplasty: Tricks of the trade
A. Nadu, Israel
 
Robotic pyeloplasty: Where we are?
A. Mottrie, Belgium
 
              
             
16:30-17:00
Coffee Break and Poster Viewing
 
 
 
17:00-18:30 Session 20
SATELLITE SYMPOSIUM:
ADVANCES IN THE THERAPY OF PROSTATE CANCER-INDUCED BONE DISEASE:

CURRENT INSIGHTS AND FUTURE PERSPECTIVES

Chairperson:
K. Miller, Germany
     

Future perspectives in the management of prostate cancer-induced bone disease

B. Tombal, Belgium
 

RANKL inhibition in men with prostate cancer

A. Stenzl, Germany
 

Case presentation and discussion

K. Miller, Germany
 
      
      
 
17:00-18:30 Session 21
SATELLITE SYMPOSIUM:
PROSTATE CANCER - Fine-tuning hormonal therapy
Chairperson: L. Boccon-Gibod, France
    
       
How is hormone therapy prescribed in France?
The "CAPITAL" study
A. de la Taille, France
 
Non-controversial indications of hormone therapy: Metastatic and locally advanced cancer
P. Rischmann, France
 
The selective indications of hormone therapy: Clinically localized cancer, biological relapse after local treatment
N. Mottet, France
 
Hormonal therapy for prostate cancer: A holistic view
J. Irani, France
 
Hormone therapy: From guidelines to real-life clinical practice
P. Perrin, France
    
   
 18:30-19:00 CURy Happy Hour

Home    Scientific Committee    Abstracts    Registration     Accommodation     Sponsorship & Exhibition    General Information    Contact Us   
Copyright © 2007 comtecmed.com. All rights reserved. Created by     WebStudio.co.il